Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
-          Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western blot, and significant improvement in histology in first three treated patients at 24-week timepoint -          Efficacy
Toggle Summary Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
- ASPIRO update to include 24-week clinical data and muscle biopsy results from the first three treated patients - Conference call and webcast scheduled for Tuesday, August 7, 2018 at 8:00am EST SAN FRANCISCO , July 31, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a
Toggle Summary Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
SAN FRANCISCO , June 5, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the European Medicines
Toggle Summary Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
SAN FRANCISCO , June 5, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the European Medicines
Toggle Summary Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
SAN FRANCISCO , May 29, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
SAN FRANCISCO , May 29, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
- Significant improvements in neuromuscular and respiratory function at 24-week timepoint - Encouraging initial efficacy observed at four-week timepoint in Cohort 1 expansion patients - Patient 1 has achieved ventilator independence and oral feeding SAN FRANCISCO , May 16, 2018 /PRNewswire/ --
Toggle Summary Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
- Significant improvements in neuromuscular and respiratory function at 24-week timepoint - Encouraging initial efficacy observed at four-week timepoint in Cohort 1 expansion patients - Patient 1 has achieved ventilator independence and oral feeding SAN FRANCISCO , May 16, 2018 /PRNewswire/ --
Toggle Summary Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
- Completed dosing of three additional patients as an expansion of the first dose cohort of ASPIRO, the Phase 1 / 2 clinical study of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) - Plan to report additional interim data from ASPIRO during an oral presentation at the 21st Annual
Toggle Summary Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
- Completed dosing of three additional patients as an expansion of the first dose cohort of ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) - Plan to report additional interim data from ASPIRO during an oral presentation at the 21st Annual